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IMMEDIATE COMMUNICATION
A rare missense mutation in CHRNA4 associates with smoking
behavior and its consequences
TE Thorgeirsson1, S Steinberg1, GW Reginsson1, G Bjornsdottir1, T Rafnar1, I Jonsdottir1,2, A Helgadottir1, S Gretarsdottir1,
H Helgadottir1, S Jonsson2,3, SE Matthiasson4, T Gislason2,3, T Tyrﬁngsson5, T Gudbjartsson2,6, HJ Isaksson7, H Hardardottir3,
A Sigvaldason3, LA Kiemeney8,9, A Haugen10, S Zienolddiny10, HJ Wolf11, WA Franklin12, A Panadero13, JI Mayordomo14, IP Hall15,
E Rönmark16,17, B Lundbäck16,18, A Dirksen19, H Ashraf19,20, JH Pedersen21, G Masson1, P Sulem1, U Thorsteinsdottir1,
DF Gudbjartsson1 and K Stefansson1,2
Using Icelandic whole-genome sequence data and an imputation approach we searched for rare sequence variants in CHRNA4 and
tested them for association with nicotine dependence. We show that carriers of a rare missense variant (allele frequency = 0.24%)
within CHRNA4, encoding an R336C substitution, have greater risk of nicotine addiction than non-carriers as assessed by the
Fagerstrom Test for Nicotine Dependence (P= 1.2 × 10− 4). The variant also confers risk of several serious smoking-related diseases
previously shown to be associated with the D398N substitution in CHRNA5.We observed odds ratios (ORs) of 1.7–2.3 for lung cancer
(LC; P= 4.0 × 10− 4), chronic obstructive pulmonary disease (COPD; P= 9.3 × 10− 4), peripheral artery disease (PAD; P= 0.090) and
abdominal aortic aneurysms (AAAs; P= 0.12), and the variant associates strongly with the early-onset forms of LC (OR = 4.49,
P= 2.2 × 10− 4), COPD (OR= 3.22, P= 2.9 × 10− 4), PAD (OR= 3.47, P= 9.2 × 10− 3) and AAA (OR= 6.44, P= 6.3 × 10− 3). Joint analysis of
the four smoking-related diseases reveals signiﬁcant association (P= 6.8 × 10− 5), particularly for early-onset cases (P = 2.1 × 10− 7).
Our results are in agreement with functional studies showing that the human α4β2 isoform of the channel containing R336C has
less sensitivity for its agonists than the wild-type form following nicotine incubation.
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INTRODUCTION
Smoking is a risk factor for many serious diseases and a leading
cause of preventable deaths worldwide.1 Genome-wide associa-
tion studies relying on common markers have yielded loci
associating with smoking behavior, including genomic regions
containing genes encoding various subunits of nicotinic
acetylcholine receptors (nAChRs) on chromosomes 15q25
(CHRNA5/CHRNA3/CHRNB4),2,3 8p11 (CHRNB3/CHRNA6)3 and
recently 20q11 (CHRNA4).4 Sequence variants within the
CHRNA5/CHRNA3/CHRNB4 cluster on chromosome 15q25 have
been shown to associate with the number of cigarettes smoked
per day (CPD),2,5 nicotine dependence (ND)2,6 and the smoking-
related diseases lung cancer (LC),2,7–9 peripheral arterial disease
(PAD),2 chronic obstructive pulmonary disease (COPD)10 and
upper aerodigestive tract cancer.11 The role of the CHRNA5/
CHRNA3/CHRNB4 locus for smoking, ND and the consequences of
smoking was established through human genetics approaches,
and these initial ﬁndings have paved the way for basic research
aimed at elucidating the underlying mechanisms.12
nAChR channels are pentameric and comprised of various types
of subunits. Twelve α subunits and three β subunits have been
cloned, and various isoforms containing both α4 and β2 subunits
are the most abundant in mammalian brain.13 nAChRs have a
large dynamic range with respect to agonist activation, but this is
partially explained by the presence of heteromers with different
stoichiometric composition of subunits with different sensitivities.
Measurements indicate that (α4)3(β2)2 is a low-sensitivity subtype
(LS), whereas (α4)2(β2)3 is of high sensitivity (HS).
14 Chronic
nicotine exposure upregulates nAChRs in a complex process
involving molecular chaperoning,15,16 and upregulation of α4β2
receptors by nicotine favors the HS form.17 Lowered sensitivity to
psychoactive drugs is generally believed to correlate with
increased risk of substance dependence, and it has been
suggested that increased expression of LS relative to HS nAChRs
in the central nervous system would increase risk of ND.18
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Results of animal studies indicate that both α4 and β2 subunits
inﬂuence key addiction-related processes.13 CHRNA4 and CHRNB2
have long been considered among the strongest functional
candidate genes in the genome when it comes to nicotine
addiction and related phenotypes, and an efﬁcacious smoking
cessation aid (varenicline) was developed as a partial agonist of
the α4β2 isoforms.19 A large number of candidate gene studies
have targeted CHRNA4 and CHRNB2, but the results have been
inconclusive. In a companion paper4 we show that common
markers within CHRNA4 exhibit genome-wide signiﬁcant associa-
tion with score on the Fagerström Test of Nicotine Dependence
(FTND),20 the most widely used measure of nicotine addiction. The
genome-wide association study of FTND was limited to the study
of common variants,4 and here we study rare variants within
CHRNA4, by testing eight missense variants in CHRNA4 for
association with FTND.
MATERIALS AND METHODS
Study populations
The Icelandic studies include a number of ongoing projects in
Iceland. All Icelandic studies were approved by the Icelandic Data
Protection Authority and the National Bioethics Committee. All
subjects who donated samples also signed informed consent.
Personal identiﬁers of the patients and biological samples were
encrypted by a third-party system provided by the Icelandic Data
Protection Authority. In addition, replication studies were
performed by genotyping samples from a number of studies
conducted elsewhere. All subjects in these studies gave written
informed consents and are of European origin. The association
studies of the variants were performed using genotypes from
whole-genome sequence data and imputation approaches
previously outlined.21 Further details of the various studies
involved are provided below (also see Results and Tables).
Smoking phenotypes
The discovery sample utilized FTND data from questionnaires
answered by participants in deCODE’s study of ND.2,3 Responses
to FTND questions generate a score of 0–10, with higher scores
representing greater ND.20 Information on smoking quantity (SQ)
was also utilized, but SQ was available from a standardized
smoking questionnaire used in deCODE’s studies that asks: ‘How
many cigarettes per day do/did you smoke on average (on most
days)?’ This means that current smokers answer their current
consumption and former smokers refer to their consumption in
the past. In cases where multiple records were available we
recorded the maximum. The SQ was categorized into four levels,
(1–10, 11–20, 21–30 and 31+ CPD). A total of 40 573 subjects
(34 200 chip-typed) were included in the R336C analysis. Ever
smokers were recruited in the years 1997–2014 as part of various
Icelandic studies, and the FTND questionnaires were administered
to participants in the study of ND (2004–2014). Analysis of subjects
with complete FTND data showed that of those reporting 1–10
CPD, 85% had a total score of 3 or less on the FTND, and o3%
scored above 6 on the FTND. We included 4313 chip-typed
low-quantity smokers (CPDo11) but without additional FTND
items answered to the FTND 0–3 group for the meta analysis of
common marker association with FTND.4 In our studies of R336C
we included additional low-quantity smokers in this category,
bringing the total number in the category to 18 184, with 15 527
chip-typed. The number of subjects per category were for R336C
analysis:
FTND 0–3 (mild ND): 18 184 (15 527 chip-typed)
FTND 4–6 (moderate ND): 2008 (1980 chip-typed)
FTND 7–10 (severe ND): 1106 (1085 chip-typed).
Smoking-related diseases
Lung cancer
Iceland: The Icelandic LC study has been described previously.2
The primary source of information on the Icelandic LC cases is the
Icelandic Cancer Registry, which covers the entire population of
Iceland (http://www.cancerregistry.is). Brieﬂy, according to the
Icelandic Cancer Registry, a total of 4560 LC patients were
diagnosed from 1 January 1955 to 31 December 2012. Recruit-
ment of both prevalent and incident cases was initiated in 1998,
the recruitment is ongoing and DNA samples from LC cases were
subjected to whole-genome genotyping as they are collected. The
LC associations were based on 1437 chip-typed LC cases (median
age 70 years, range 16–97, 48% males) and 84 086 chip-typed
controls in addition to 2572 LC cases and 137 443 controls
who had at least one of their ﬁrst- or second-degree relatives
chip-typed. To study early-onset LC we considered subjects
diagnosed before reaching an age of 58 years.
Nijmegen, The Netherlands: The Dutch study population was
previously described.22 The 634 patients with LC were identiﬁed
through the population-based cancer registry of the Comprehen-
sive Cancer Center IKO, Nijmegen, the Netherlands, and recruited
through several independent studies.22 The 4670 cancer-free
controls were selected from participants of the ‘Nijmegen
Biomedical Study’.23 All controls are of self-reported European
descent. The study protocols of the Nijmegen Biomedical Study
were approved by the Institutional Review Board of the Radboud
University Nijmegen Medical Centre.
Table 1. Association of eight rare missense variants in CHRNA4 with FTND
Variant P-value Effect MAF (%) Imp Inf Position Minor allele Major allele Coding effect
chr20:61451525:S 0.37 − 0.71 0.017 0.88 61 451 525 A G S561L
rs77345643 0.099 0.91 0.038 0.73 61 451 540 A G P556L
rs55915440 0.48 0.063 1.378 0.96 61 451 855 A G P451L
rs121912272 0.76 − 0.042 0.547 0.91 61 451 979 T C V410I
rs56175056 1.2 × 10− 4 0.85 0.237 0.99 61 452 201 A G R336C
chr20:61457796:S 0.15 0.41 0.127 0.96 61 457 796 A G R120W
chr20:61457871:S 0.68 0.28 0.05 0.44 61 457 871 G C D95H
chr20:61461433:S 0.013 0.61 0.61 0.97 61 461 433 T C G47S
Abbreviations: FTND, Fagerström Test of Nicotine Dependence; Imp, imputation; Inf, information; MAF, minor allele frequency. Table 1 shows association
results for non-synonymous variants in CHRNA4 identiﬁed by sequencing 2636 Icelanders and imputing their variants into 104,220 Icelanders for the FTND run
as a quantitative trait using three categories (FTND 0–3=mild, FTND 4–6=moderate and FTND 7–10= severe). Shown are identity of variant (rs names where
available), P-value of association, effect size, minor allele frequency in Iceland (in %), imputation information, position of each variant on chromosome 20 in
build 36, identity of minor and major alleles, and the coding effect of the variant. The reported effect size is in FTND units, obtained by multiplying the effect
size from analysis with 3.5, the difference between midpoints of adjacent categories.
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Zaragoza, Spain: The Spanish study population was previously
described.22 The 455 LC cases were recruited from the Oncology
Department of Zaragoza Hospital in Zaragoza, from June 2006
to June 2009. The 1444 Spanish controls were patients at the
University Hospital in Zaragoza for diseases other than cancer,
between November 2001 and May 2007. Study protocols were
approved by the Institutional Review Board of Zaragoza University
Hospital.
Denver, Colorado: DNA samples from blood and clinical data
were provided by the University of Colorado Cancer Center under
COMIRB protocol 08–0380. Blood samples were collected from
1217 patients diagnosed with different diseases enrolled in any of
20 clinical research trials carried out at Colorado SPORE protocols
between 1993 and 2008. Of these 1217 patients, 246 were LC
cases and 971 had never had LC at the time of sample shipment.
LC cases were identiﬁed either from data matches with the
Colorado Central Cancer Registry or by having malignant lung
tissue collected via enrollment in a surgical protocol. Work in this
study was limited to cases and controls of self-reported European
ancestry (195 cases and 798 controls).
Norway: Comprehensive details of cases and controls have been
previously published.24 Brieﬂy, a systematic series of 426 patients
with histologically proven non-small cell LC treated with surgery
were ascertained through university hospitals in Oslo or Bergen
between 1986 and 2001. All of the cases were either smokers at
the time of surgery or ex-smokers. Healthy controls were recruited
from a general health survey of individuals conducted by the
National Health Surveys in the Oslo area (HUBRO) between 2000
and 2001, or in western Norway. Among them, smokers without
any known history of cancer were randomly selected and
frequency matched to the cases on age, smoking dose (pack-
years) and gender. Cases and controls were interviewed using
questionnaires that allowed collection of the same demographic
and lifestyle information. Both cases and controls were
Norwegians of European descent. The study was approved by
the regional ethical committee in accordance with the Helsinki
Declaration.
Chronic obstructive pulmonary disease
Iceland: COPD was deﬁned broadly and included diagnoses of
chronic bronchitis or emphysema made between 1980 and 2011 at
the Landspitali University Hospital. A total of 8246 subjects born
between 1883 and 1964 were included, with most (5871) of the
conﬁrmed COPD diagnoses made during the years 1998–2011. The
actual age at onset of COPD is difﬁcult to assess, as patients have
usually had signs and symptoms for a long time before admission
to hospital. To deﬁne an early-onset group we used year of birth as
a surrogate, using the group born between 1940 and 1964
(N=1470) representing the youngest 19.6% of patients. Association
analyses were based on 3857 chip-typed cases, and 3639 patients
with at least one ﬁrst- or second-degree relative chip-typed.
United Kingdom: A total of 206 subjects with COPD deﬁned by
spirometry (forced expiratory volume (FEV)/forced vital capacity
(FVC) o0.7, FEV1% o80%), over 40 years of age, and 338
controls, as part of the Nottingham Smokers Study.25
Sweden: Participants in a population study on COPD in Norrbotten
(Olin study), Sweden.26 Those who answered questionnaire were
followed up with spirometry and blood sample; 581 COPD patients
(deﬁned by spirometry (FEV1/FVCo0.7 and FEV1o80% of
predicted values) or (FEV1/FVCo0.7)) and 918 controls.
Denmark: Participants in a LC screening study of 4104 current or
previous smokers (2004–2006),27 708 were diagnosed with COPD
based on sprirometry (FEV1/FVCo0.7) and emphysema based on
high resolution computed tomography scan.
Peripheral arterial disease
Iceland: The study population has been described previously.2
Brieﬂy, Icelandic individuals with PAD were recruited from a
registry of individuals diagnosed with PAD at the Landspitali
University Hospital, during the years 1983–2011. The PAD
diagnosis was conﬁrmed by vascular imaging or segmental
pressure measurements. To study early-onset PAD we considered
subjects diagnosed with PAD before reaching age 65.
Abdominal aortic aneurysm
Iceland: Icelanders with abdominal aortic aneurysms (AAAs)
were recruited from a registry of individuals who were admitted
either for emergency repair of symptomatic or ruptured AAA, or
for an elective surgery to the Landspitali University Hospital, in
Reykjavik, Iceland, in 1980–2011. Individuals (with an unruptured
aneurysm⩾ 30 mm) were also recruited through a high-risk
screening of ﬁrst-degree relatives of AAA patients. To study
early-onset AAA we considered subjects diagnosed with AAA
before reaching age 65.
Single-track assay single-nucleotide polymorphism genotyping:
Single single-nucleotide polymorphism (SNP) genotyping was
carried out by deCODE Genetics in Reykjavik, Iceland, applying the
Centaurus (Nanogen) platform.7 The same assay was used to
obtain genotypes for rs56175056 on three COPD sample sets,
from the United Kingdom, Sweden and Denmark, as well as LC
cases and controls from the Netherlands, Spain, the United States
and Norway.
Illumina SNP chip genotyping: The Icelandic chip-typed samples
were assayed with the Illumina HumanHap300, HumanCNV370,
HumanHap610, HumanHap1M, HumanHap660, Omni-1, Omni 2.5
or Omni Express bead chips (Illumina, San Diego, CA, USA) at
deCODE genetics. SNPs were excluded if they had (i) yield lower
than 95%, (ii) minor allele frequency o1% in the population, (iii)
signiﬁcant deviation from Hardy–Weinberg equilibrium in the
controls (Po0.001), (iv) if they produced an excessive inheritance
error rate (over 0.001) or (v) if there was substantial difference in
allele frequency between chip types (from just a single chip if the
problem that resolved all differences, but from all chips
otherwise). All samples with a call rate below 97% were excluded
from the analysis. For the HumanHap series of chips, 308 840
SNPs were used for long-range phasing, whereas for the Omni
series of chips 642 079 SNPs were included.
Whole-genome sequencing and SNP calling: SNPs were imputed
based on whole-genome sequence data from about 2636
Icelanders, selected for various neoplastic, cardiovascular, meta-
bolic and psychiatric conditions. The sample preparation, DNA-
sequencing methodology, alignment and BAM ﬁle generation
have been described previously.21
Genotype imputation methods
Long-range phasing and genotype imputation: Long-range
phasing of all chip-genotyped individuals was performed with
methods described previously,21 and imputed into chip-typed
individuals and their close relatives using methods21 based on
IMPUTE.28 In brief, phasing is achieved using an iterative
algorithm, which phases a single proband at a time given the
available phasing information about everyone else that shares a
long haplotype identically by state with the proband. Given the
large fraction of the Icelandic population that has been
chip-typed, accurate long-range phasing is available genome
wide for all chip-typed Icelanders. The informativeness of
genotype imputation was estimated by the ratio of the variance
of imputed expected allele counts and the variance of the actual
allele counts:
I=Var[E(θ|chipdata)]/Var(θ)
where θ∈ {0,1}is the allele count. Var[E(θ|chipdata)] was estimated
by the observed variance of the imputed expected counts and Var
(θ) was estimated by p(1− p), where p is the allele frequency. For
Missense mutation in CHRNA4
TE Thorgeirsson et al
596
Molecular Psychiatry (2016), 594 – 600 © 2016 Macmillan Publishers Limited
further information on the imputation methodology see previous
descriptions of our methods.21
Association analysis. The details of our methodology for associa-
tion analysis have been described,21 but a brief description is
provided below.
Case:control association testing: Logistic regression was used to
test for association between SNPs and disease, treating disease
status as the response and expected genotype counts from
imputation or allele counts from direct genotyping as predictor.
Testing was performed using the likelihood ratio statistic. When
testing for association using the imputed genotypes, controls
were matched to cases based on the informativeness of the
imputed genotypes, such that for each case controls of matching
informativeness were chosen. Failing to match cases and controls
will lead to a highly inﬂated genomic control factor, and in some
cases may lead to spurious false-positive ﬁndings.
Quantitative traits: A generalized form of linear regression was used
to test the correlation between the variants tested and quantitative
traits (FTND and CPD) in Iceland. The generalized form assumes that
the smoking behavior of related individuals is correlated proportional
to the kinship between them rather than assuming that the smoking
phenotypes of all individuals are independent.
Inﬂation factor adjustment: In order to account for the relatedness
and stratiﬁcation within the case and control sample sets we applied
the method of genomic control based on chip-typed markers using
a subset of about 300 000 common variants. Quoted P-values were
adjusted accordingly. The inﬂation factors for the various analyses
are listed in the Supplementary Material.
Analysis of replication data: Association analysis for each
replication study group was carried out using Fisher’s exact text,
and results for different study groups were combined using the
Mantel–Haenszel exact test.
RESULTS
To search for rare variants likely to inﬂuence function in CHRNA4
we analyzed whole-genome sequence data from 2636 Icelandic
subjects, identifying eight non-synonymous variants present in
high enough frequency to allow imputation into our long-range
phased data set21 (usually approximately ﬁve carriers in our
sequence data, currently corresponding to an allele frequency
of about 0.1%), generating genotypes for 104 220 chip-typed
Icelanders and 294 212 close relatives. Eight variants met our
criteria, and following imputation they were tested for association
with the FTND score (Table 1) with the signiﬁcance threshold set at
P=6.25×10− 3 (0.05/8). The mutation encoding R336C associates
with FTND score (P=1.2 × 10−4), whereas none of the other
mutations tested showed signiﬁcant association (Table 1). To
improve imputation accuracy, we typed 1441 subjects for the
R336C variant using a single-marker assay (Nanogen) and repeated
the imputation process. As a result of this effort the imputation
information increased from 0.939 to 0.999, and all results
reported here were based on re-imputed data. On the basis
of 1408 (original imputation) or 1441 individuals (re-imputation)
with both typed and imputed genotypes the imputation accuracy
for this variant as estimated by the correlation with typed
genotypes changed from 0.946 (original imputation) to 0.997
(re-imputation).
There is some evidence for a founder effect as the frequency of
R336C (0.24%) is higher in the Icelandic population than in any
other population with a reported frequency. In the ExAC Browser
(www.exac.broadinstitute.org), 31 carriers of R336C are reported in
non-Finnish European populations, indicating an allele frequency
of 0.046%. The variant was not detected in Asian or Latino
populations, and 2 carriers from African populations (f= 0.019%)
are reported.
To explore this association further we also examined association
of the variant coding for R336C substitution with several
sub-phenotypes related to nicotine addiction and the health
consequences of smoking (Table 2). In selecting the smoking
phenotypes and smoking-related diseases to study we were
guided by previously observed associations between the key
variant in CHRNA5, rs1051730/rs16969968 and CPD, LC, PAD,
COPD and upper aerodigestive tract cancers.12 In addition,
we have observed association of rs1051730-A with AAAs in
Iceland (odds ratio (OR) = 1.19, P= 0.009). As a subtype of ND
we also include the heavy smoking index,29 a measure that
Table 2. CHRNA4 R336Ca confers risk of heavy smoking and smoking-related diseases
Phenotype Eff/OR P-value Cases Controls
N chip N rel N chip N rel
FTND score (mild, moderate, severe) 0.85b 1.2 × 10− 4 18 592 2706 — —
CPD in smokers 3.0 CPD 1.8 × 10− 4 34 200 6373 — —
HSI score 4+ vs low-quantity smokersc 4.77 2.1 × 10− 5 1713 31 13 948 1.064
LC 2.29 4.0 × 10− 4 1437 2572 84 086 137 443
Early-onset LC 4.49 2.2 × 10− 4 245 583 85 273 129 010
PAD 1.66 0.090 1926 961 81 992 109 548
Early-onset PAD 3.47 9.2 × 10− 3 447 81 70 988 69 570
COPD 1.91 9.3 × 10− 4 3857 3639 87 510 207 914
Early-onset COPD 3.22 2.9 × 10− 4 1033 437 64 979 73 138
AAAs 1.98 0.12 574 686 83 349 122 962
Early-onset AAA 6.44 6.3 × 10− 3 92 112 83 831 123 536
All smoking-related diseases 1.87 6.8 × 10− 5 6594 6910 84 776 225 225
All smoking-related diseases early onset 3.48 2.1 × 10− 7 1704 1178 83 818 138 837
Abbreviations: AAA, abdominal aortic aneurysm; COPD, chronic obstructive pulmonary disease; CPD, cigarettes smoked per day; FTND, Fagerström Test of
Nicotine Dependence; HSI, heavy smoking index; LC, lung cancer; OR, odds ratio; PAD, peripheral artery disease; SNP, single-nucleotide polymorphism. Table 2
shows the results of association analyses of two quantitative traits, nicotine dependence (FTND score) and smoking quantity (CPD), and case–control
comparisons for a number of smoking-related diseases. Shown are, for each of the phenotypes listed, the effect sizes (Eff ) for quantitative traits or ORs for
case–control comparisons, the P-value and for both cases and controls, the number of subjects included in analysis, chip-typed individuals (N chip) and those
with at least one ﬁrst- or second-degree relative typed (N rel). The inﬂation factors for the various analyses listed are provided in the Supplementary Material.
aThe SNP encoding R336C (rs56175076) has position 61 452 201 on chromosome 20 according to build 36 (hg18). bEffect size from analysis multiplied by 3.5,
the difference in FTND score between the category midpoints; for information on the FTND analysis see Materials and Methods. cHSI29 vs smokers smoking 10
CPD or less.
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combines two of the key questions on the FTND,20 SQ and the
time to ﬁrst cigarette after waking up, with a score of 4 or higher
being considered high and comparable to an FTND score of ~ 6.30
For the smoking-related diseases we also considered the effect
of the variant in early-onset cases separately (Materials and
Methods).
All the smoking-related diseases with observed associations
with rs1051730/rs16969968 show some evidence of association
with R336C (Table 2), and the effects are larger for early-onset
groups. Many of the phenotypes tested are correlated, such
that the individual associations with the different smoking-
related diseases cannot be considered independent. To assess
the overall signiﬁcance of the effect that the variant has
on the smoking-related diseases we combined the lists and
assessed the whole group for association with R336C. This is
justiﬁed by the fact that the difference between the smoking-
related diseases can be looked upon as variation in expressivity of
one environmental factor, namely tobacco smoke. The overall P-
values obtained from this analysis are 6.8 × 10− 5 and 2.1 × 10− 7
for the total and early-onset smoking-related diseases, respec-
tively, providing an estimate of the combined strength of the
evidence for association with the health consequences of smoking
(Table 2).
Although the associations with smoking-related diseases do not
represent a fully independent replication of the FTND result, we
note that because we often lack detailed information on smoking
for subjects with smoking-related diseases there is very little
overlap between the group of subjects with FTND data and those
with smoking-related diseases. For example, only 140 subjects are
both on the early-onset smoking-related disorders list and among
the subjects scoring 4 or higher on the heavy smoking index,
representing ~ 8% of the heavy smoking index cases and 4.7% of
the subjects with early-onset smoking-related diseases. The overlap
between these lists is so small because only a few of the patients
with early-onset smoking-related disorders have ﬁlled out the FTND
questionnaire. Hence, despite the correlation between smoking
behavior and the smoking-related diseases our results for FTND and
the smoking-related diseases are not due to direct confounding as
there is very little overlap between the study groups. Furthermore,
as was the case for CHRNA5 (refs 2,31,32) the observed effect on
FTND and CPD alone is not expected to fully explain the observed
OR for smoking-related diseases.
The associations between the R336C variant and the
various smoking-related phenotypes are not explained by
associations with common markers nearby, nor does the variant
explain the association with rs2273500, the SNP most strongly
associated in the meta analysis study of FTND,4 as the rare
missense variant is ﬁxated on the protective background of
rs2273500. For the results of detailed conditional analyses see
Supplementary Material.
We attempted replication studies of the ﬁndings for the R336C
variant, focusing on LC (1710 cases and 7670 controls) and COPD
(1495 cases and 2180 controls), using a single SNP assay for
genotyping (Table 3). Combining both phenotypes, the OR was 2.3
(P= 0.25). The low allele frequencies in these populations mean
that we lack power to obtain meaningful results with the sample
sizes studied, with only 10 carriers observed in 13 055 samples
(average allele frequency of 0.038%).
DISCUSSION
A recent study of rare variants in CHRNA4 based on a comparison of
sequence data for exon 5 for 1209 cases and 1183 controls
observed that rare non-synonymous variants were underrepre-
sented in nicotine-dependent subjects, and the authors concluded
that such variants might be protective against ND.33 In the case of
R336C, our results clearly show the opposite, namely that the
variant encoding this mutation confers risk of ND and its
consequences on health, and comparison of the results for the
various variants such as P451L and R336C reveals a range of effect
sizes (Table 1), suggesting that treating all rare missense variants in
CHRNA4 alike is not a good approach. We note that only one carrier
of R336C was observed by Xie et al.,33 a case with ND.
In a follow-up to the aforementioned study,33 three variants of
human CHRNA4 (encoding for the substitutions R336C, P451L and
R487Q) were subjected to detailed functional studies in Xenopus
laevis oocytes.18 Electrophysiological studies found changes in the
activation by nAChR agonists in channels containing these α4 rare
variants, including changes following incubation with nicotine.
The authors concluded that sequence variation at CHRNA4 alters
the assembly and expression of human α4β2 nAChRs, resulting in
receptors that are inﬂuenced to a greater extent by nicotine
exposure than channels containing the common α4 variant.
Speciﬁcally, incubation of oocytes transfected with the α4R336C
variant with nicotine for 24 h had the same effect on nicotine-
evoked currents as observed with ACh, revealing a shift in agonist
effect that produced a large LS response. Both α4R336C and
α4R487Q showed a shift from a monophasic, HS relationship to
Table 3. Results of replication studies for R336C
Sample P-value OR N cases AF cases N ctrls AF ctrls Carriers
Cases Ctrls
LC
The Netherlands 0.32 3.7 634 7.9 × 10− 4 4670 2.1 × 10− 4 1 2
Spain 1 0 455 0 1444 3.5 × 10− 4 0 1
USA 0.10 8.2 195 5.1 × 10− 3 798 6.3 × 10− 4 2 1
Norway — — 426 0 758 0 0 0
All LC 0.098 3.8 1710 — 7670 —
COPD
UK 1 1.6 206 2.4 x 10− 3 338 1.5 × 10− 3 1 1
Sweden — — 581 0 918 0 0 0
Denmark 1 0 708 0 924 5.4 × 10−4 0 1
All COPD 1 0.8 1495 — 2180 —
Abbreviations: COPD, chronic obstructive pulmonary disease; LC, lung cancer; OR, odds ratio. Table 3 shows the results from replication studies of the R336C in
populations outside of Iceland. Listed are for each sample set: P-value, OR, number of cases and controls (N cases and N ctrls), allele frequencies (AF cases and
AF ctrls) and the number of observed carriers for cases and controls.
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biphasic activation, with both variants gaining LS activation
components. The size of the LS component was particularly large
for α4R336C (see Figure 4 in McClure-Begley et al.18). Such an
effect was not seen for α4P451L18 consistent with the lack of
association with FTND for the P451L variant (Table 1).
We have presented several lines of evidence for the role of a
variant encoding R336C in smoking behavior and risk of smoking-
related diseases. The variant is rare, but there appears to be a
founder effect in Iceland, allowing us to perform association
studies with adequate power. First, there is independent and
genome-wide signiﬁcant association between common markers
and FTND in the region.4 Second, testing a small number of
missense variants in CHRNA4, we ﬁnd signiﬁcant association of the
R336C variant with FTND and other smoking behavior pheno-
types. Third, guided by previous results for CHRNA5 and smoking-
related diseases,12 we ﬁnd signiﬁcant association with four
smoking-related diseases, and highly signiﬁcant association with
the early-onset forms. Fourth, functional data show that the R336C
substitution inﬂuences function, shifting the equilibrium following
nicotine exposure in favor of a lower-sensitivity form.18 When
taken together, these results allow us to conclude that carriers of
this variant have increased risk of nicotine addiction and heavy
smoking, which in turn confers considerable risk and lowered age
of onset for a number of serious smoking-related diseases through
gene–environment correlations34 akin to those previously
observed for the D398N mutation in CHRNA5.2,12
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